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Abstract
The detection of epistatic interactive effects of multiple genetic variants on the susceptibility of human complex diseases is
a great challenge in genome-wide association studies (GWAS). Although methods have been proposed to identify such
interactions, the lack of an explicit definition of epistatic effects, together with computational difficulties, makes the
development of new methods indispensable. In this paper, we introduce epistatic modules to describe epistatic interactive
effects of multiple loci on diseases. On the basis of this notion, we put forward a Bayesian marker partition model to explain
observed case-control data, and we develop a Gibbs sampling strategy to facilitate the detection of epistatic modules.
Comparisons of the proposed approach with three existing methods on seven simulated disease models demonstrate the
superior performance of our approach. When applied to a genome-wide case-control data set for Age-related Macular
Degeneration (AMD), the proposed approach successfully identifies two known susceptible loci and suggests that a
combination of two other loci—one in the gene SGCD and the other in SCAPER—is associated with the disease. Further
functional analysis supports the speculation that the interaction of these two genetic variants may be responsible for the
susceptibility of AMD. When applied to a genome-wide case-control data set for Parkinson’s disease, the proposed method
identifies seven suspicious loci that may contribute independently to the disease.
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Introduction
With the development of modern human and medical genetics,
it has been widely accepted that genetic variation plays an
important role in the pathogenesis of genetic inherited diseases [1].
The identification of causative genetic variants therefore becomes
the primary step towards the understanding of genetic principles
underlying these diseases. For Mendelian diseases in which an
individual genetic variant in a single gene is both sufficient and
necessary to cause a disease, classical statistical approaches such as
linkage analysis [2–5] and association studies [6,7] have shown
remarkable successes in the identification of causative genetic
variants. Nevertheless most common diseases are complex ones
that are supposed to be caused by multiple genetic variants, their
interactive effects, and/or their interaction with environment
factors [7,8]. The detection of such interactive effects therefore
plays a key role in the understanding of these diseases.
The interactive effects of multiple genetic variants underlying
complex diseases are often referred to as epistasis or epistatic
interactions. Recent advances in biomedical studies have been
confirming the contribution of epistasis to complex diseases. For
example, Tiret et al reported synergistic effects of polymorphisms
in the angiotensin-converting enzyme and the angiotensin-II type
1 receptor gene on the risk of myocardial infarction [9]. Ritchie et
al identified the association of a high-order interaction among four
polymorphisms in three estrogen-metabolism genes with breast
cancer [10]. Williams et al reported the influence of a two-locus
interaction between polymorphisms in the angiotensin converting
enzyme and the G protein-coupled receptor kinase on hyperten-
sion susceptibility [11]. Tsai et al identified the association of a
three-locus interaction among polymorphisms in renin-angiotensin
system genes with atrial fibrillation [12]. Cho et al reported the
association of a two-locus interaction between polymorphisms in
the uncoupling protein 2 gene and the peroxisome proliferator-
activated receptor gamma gene with Type 2 diabetes mellitus [13].
Martin et al reported the influence of a two-locus interaction
between polymorphisms in KIR3DL1 and HLA-B on both AIDS
progression and plasma HIV RNA [14]. With these examples,
epistasis between multiple genetic variants is now widely believed
to be the causative pattern of human complex diseases.
In order to detect epistasis, a number of multi-locus approaches
have been developed. For example, Hoh et al proposed a
trimming, weighting, and grouping approach that used the
summation of statistics on the basis of single-locus marginal effects
and the Hardy-Weinberg equilibrium (HWE) for hypothesis
testing [15]. Nelson et al proposed a combinatorial partitioning
method (CPM) that exhaustively searched for a combinatory
genotype group that had the most significant difference in the
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et al proposed a restricted partitioning method (RPM) which
modified CPM by ignoring partitions that combined individual
genotypes with very different mean trait values [17]. Millstein et al
proposed a focused interaction testing framework (FITF) in which
a prescreening strategy was developed to reduce the number of
tests [18]. Chatterjee et al used Turkey’s 1-degree-of-freedom
model to detect interacting loci from different regions [19]. Ritchie
et al proposed a multifactor-dimensionality reduction (MDR)
method in which exhaustive search was performed to detect
combinations of loci with the highest classification capability [10].
Although these methods have shown their successes in
association studies for small scale candidate genes [10,15–19],
their effectiveness for large scale case-control data has not yet been
validated. Besides, most of the methods rely strongly on exhaustive
search for combinations of multiple loci. This search strategy,
though feasible when the number of candidate genetic variants is
small, can hardly be computationally practical for large scale or
whole-genome association studies in which the number of
candidate genetic variants is typically very huge. For example, a
study on Age-related Macular Degeneration (AMD) has geno-
typed more than 100 thousand single nucleotide polymorphism
(SNP) markers for 96 patients and 50 unaffected people [20], and a
recent genome-wide association study on Parkinson’s disease has
genotyped more than 400 thousand SNP markers for 270 patients
and 271 unaffected people [21,22]. With such dense SNPs being
genotyped, methods based on exhaustive search are computation-
ally impractical due to the vast number of possible combinations of
the SNP markers. The main challenge for genome-wide
association studies is therefore to design computational approaches
that are capable of avoiding the ‘‘combinatorial explosion’’ curse
to identify epistatic interactions.
A recent breakthrough in genome-wide epistasis mapping is the
introduction of the Bayesian epistasis association mapping (BEAM)
method [23] that integrates a Bayesian model with the Metropolis-
Hastings algorithm to infer the probability that each locus is
associated with the susceptibility of a specified disease. BEAM
classifies SNP markers into three types: SNPs unassociated with
the disease, SNPs contributing to the disease susceptibility
independently, and SNPs influencing the disease risk jointly with
each other. However, the genetic models for complex diseases
could be far more complicated than that proposed by BEAM. For
example, the disease-associated SNPs that jointly influence the
disease risk may be further divided into subgroups, in which a SNP
interacts with other SNPs in the same subgroup, but not with those
in the other subgroups. This situation could be very common in
real data, making BEAM ineffective in the exploration of true
interactive effects of multiple loci.
To overcome this limitation, in this paper, we give an explicit
presentation of ‘‘epistasis’’ and define ‘‘epistatic modules’’ as basic
units of disease susceptibility loci. On the basis of this notion, we
put forward a Bayesian marker partition model to explain the
observed case-control data and further generalize this model to
account for the existence of linkage disequilibrium (LD) between
genetic variants. To facilitate the identification of epistatic
modules, we develop a Gibbs sampling strategy with a reversible
jump Markov chain Monte Carlo (RJ-MCMC) procedure to
simulate the posterior distribution that genetic variants belong to
the epistatic modules and further resort to hypothesis testing to
screen out statistically significant modules. In contrast to most of
the existing methods that entirely or partially rely on exhaustive
search for combinations of loci, the proposed approach, named
epiMODE (epistatic MOdule DEtection), natively identifies inter-
active loci (epistatic modules) without enumerating their combi-
nations, thereby being capable of detecting interactive effects of
multiple loci from a vast number of genotyped genetic variants.
We systematically compare the proposed approach with three
existing methods on seven simulated disease models. The results
show the superior performance of our approach over the other
methods. We further apply the proposed approach to a genome-
wide case-control data set for Age-related Macular Degeneration
(AMD) that contains more than 100 thousand SNPs genotyped for
96 cases and 50 controls [20] and successfully identify two SNPs
that are known to be associated with the disease. Besides, the
results also suggest that two other SNPs (rs1394608 and
rs3743175) may have interactive effects on the susceptibility of
the disease. We also apply the proposed approach to a genome-
wide case-control data set for Parkinson’s disease (400 thousand
SNPs genotyped for 270 cases and 271 controls) [21,22] and
identify seven SNP markers that may be associated with the
disease.
Materials and Methods
Epistasis and Epistatic Modules
The concept of epistasis implies that the phenotypic effect of one
locus is dependent on one or more other loci. Nonetheless the
definitions of epistasis in biology and statistics are not exactly
consistent. Even from the statistical perspective only, researchers
have different understandings of epistasis [24,25]. Considering
these inconsistencies, it is necessary to first give a clear definition of
epistasis, for the purpose of developing a computational method
for identifying multiple loci that contribute to the disease
susceptibility.
In this paper, a locus stands for a SNP. A genotype stands for a
set of two alleles (one inherited from father and the other from
mother) at a locus and has three possible values: homozygosity of
common alleles, homozygosity of minor alleles, and heterozygos-
ity. A combinatory genotype represents the genotype of a
combination of multiple loci. For a combination of t loci, the
number of all possible combinatory genotypes is 3
t. The
penetrance of a combinatory genotype is the probability/risk that
an individual with this combinatory genotype is affected, given the
combinatory genotype of the multiple loci. We first assume that all
Author Summary
Although genome-wide association studies (GWAS) have
been quite popular due to recent advances in low-cost
genotyping techniques, most of the reported studies only
analyze single-locus effects because traditional multi-locus
methods are not computationally practical in the detection
of epistatic interactive effects of multiple loci. Here, on the
basis of a rigorous definition of epistatic modules that
describe interactive effects of multiple loci, we take
advantage of a Bayesian model with a properly designed
Gibbs sampling strategy to facilitate the detection of such
modules. We confirm via extensive simulation studies that
the proposed method, named epiMODE, is not only
feasible in detecting multi-locus effects but also more
powerful than three representative methods on seven
disease models. We apply the proposed method to an
Age-related Macular Degeneration (AMD) data and dis-
cover that a combination of two loci—one in the gene
SGCD and the other in SCAPER—might be associated with
AMD. Considering its advantages, we suggest that the
proposed method be applied to more GWAS data for the
detection of multi-locus interactive effects.
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then we generalize the definitions to the situation with linkage
disequilibrium between multiple loci.
LetL~ ‘1,   ,‘L fg bethesetofallLlociunderinvestigation,and
S~ ‘1,   ,‘s fg be the set of all s disease susceptibility loci that
determinethediseaserisk.Foranytwosubsets,S1andS2,ofS(S1(S,
S2(S,a n dS1\S2~ 6 0), their penetrance given the combinatory
genotypes GS1 and GS2 respectively, can be described as
p D GS1,GS2 j ðÞ ~fG S1,GS2 ðÞ ,
where p D : j ðÞ represents the penetrance of a given combinatory
genotype,G:acombinatorygenotypeofthemultipleloci,andf : ðÞthe
functiondenotinghow combinatorygenotypes determine thedisease
penetrance.
For any given combinatory genotypes of S1 and S2,i f
p D GS1,GS2 j ðÞ ~fG S1,GS2 ðÞ ~f1 GS1 ðÞ f2 GS2 ðÞ
is always true, the relationship between the two subsets of loci S1
and S2 is defined as ‘‘independently contributing’’ to the disease.
Otherwise, the relationship between S1 and S2 is defined as
‘‘epistasis.’’ Particularly, the relationship between a set of loci and
a null set is defined as epistasis.
A set of loci S1(S is an ‘‘epistatic module’’ if and only if the
relationship between S1 and its complement, :S1~S{S1,i s
‘‘independently contributing,’’ that is, for any given genotype GS1
and G:S1,
p D GS1,G:S1 j ðÞ ~fG S1,G:S1 ðÞ ~f1 GS1 ðÞ f2 G:S1 ðÞ ,
and the relationship between any subset of S1, S
0
1(S1, and its
complement :S
0
1~S1{S
0
1 is epistasis.
Obviously, the set of disease susceptibility loci S consists of one
or more epistatic modules. We further verify that there is no
overlap between any two epistatic modules, and epistatic modules
are independent in both case and control populations (Text S1).
In genome-wide association studies where the SNPs are quite
dense, it is common that a SNP may be in LD with other SNPs.
To account for this situation, we define a group of SNPs that are in
LD with each other as an ‘‘LD set’’ and extend the above
definition of epistatic modules by replacing individual loci with LD
sets. Note that with this extension, all properties of epistatic
modules remain unchanged, as long as we treat an LD set as an
individual locus in the previous derivation.
The mechanism how a number of susceptibility SNPs
contribute to the disease risk through epistatic modules is shown
in Figure 1. The disease risk is determined by a number of epistatic
modules, each of which contributes to the disease independent of
the others. An epistatic module is composed of one or more
susceptibility SNPs, each of which may be in LD with some other
SNPs, forming an LD set. A disease susceptibility SNP, together
with the SNPs that are in LD with it, relies on other disease
susceptibility SNPs or LD sets in the same epistatic module to
affect the disease susceptibility. An epistatic module cannot be
further divided into smaller epistatic modules; hence epistatic
modules are the smallest genetic units that independently influence
the disease risk.
Bayesian Marker Partition Model
Suppose that in a population-based case-control study, Nd cases
and Nu controls are genotyped at a number of L SNP markers.
The genotypes for cases and controls are represented as
D~ d1,   ,dNd ðÞ and U~ u1,   ,uNu ðÞ , respectively, where
di~ di1,   ,diL ðÞ
0 and uj~ uj1,   ,ujL
   0 denote the genotypes
of the i-th patient and the j-th unaffected individual at the L
markers, respectively. With the understanding of epistatic
modules, the L markers can be partitioned into Sz1 modules
M0, M1,…, MS, with M0 containing markers unlinked to the
disease and M1 to MS being epistatic modules.
Let Ii (i~1,   ,L) be an indicator of the assignment of the i-th
marker into one of the Sz1 modules, and I~ I1,   ,IL ðÞ
0 be a
vector representing the assignments for all of the L markers.
Obviously, Ii has Sz1 possible values 0,1,   ,S. Let lm be the
number of markers falling into the m-th module (m~0,1,   ,S).
We have that l0zl1z   zlS~L. Let Dm and Um be the
Figure 1. Relationship between phenotype and genotype, illustrated with epistatic modules. Disease-associated SNPs are contained in
epistatic modules. Disease-unassociated SNPs are outside the modules. SNPs with the same color form an LD set.
doi:10.1371/journal.pgen.1000464.g001
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the case and the control populations, respectively. Obviously, we
have that Di\Dj~ 6 0 when i=j and
SS
i~0 Di~D for the case
population, and Ui\Uj~ 6 0 when i=j and
SS
i~0 Ui~U for the
control population.
With these concepts, the problem of finding markers that have
epistatic interactions on the disease risk is equivalent to a problem
of assigning the markers to epistatic modules. Particularly, the
assignment for a marker can be done by first calculating the
probability of the observed data given a certain marker partition
pattern and then obtaining the posterior probability that the
marker belongs to each module using some sampling strategy. For
a clear presentation, we first derive a Bayesian model that assumes
independence between SNPs and then generalize the model to
account for the existence of LD sets.
The module M0 consists of markers that are unlinked to the
disease. Therefore, markers in D0 (the case population) should
follow the same distribution as those in U0 (the control
population). Let h0i~ h0i1,h0i2,h0i3 ðÞ , i~1,   l0, be the probabil-
ities of occurrence of the three possible genotypes for the i-th
marker in M0, and H0~ h01,   ,h0l0 ðÞ
0 be the vector that is
composed of all probabilities of genotypes of the l0 markers
belonging to M0. Let n0ik and n’0ik be the number of individuals
that have the k-th genotype at the i-th marker in the case and the
control populations, respectively. The joint distribution of the
observed genotypes D0 and U0, given the partition I and the
parameters H0 can then be written as
p D0,U0 I,H0 j ðÞ ~ P
l0
i~1
P
3
k~1
h
n0ikzn’0ik
0ik : ð1Þ
Following the Bayesian approach, we assume that every h0i
(i~1,   ,l0) follows a Dirichlet distribution with the hyper-
parameter a~ a1,a2,a3 ðÞ , that is, p h0i a j ðÞ !P3
k~1 h
ak{1
0ik . Integrat-
ing out H0 in Equation (1), we obtain
p D0,U0 I j ðÞ ~
P
l0
i~1
C
P3
k~1 ak
  
C NdzNuz
P3
k~1 ak
   P
3
k~1
C n0ikzn’0ikzak ðÞ
C ak ðÞ
0
@
1
A,
ð2Þ
where C : ðÞis the Gamma function.
For an epistatic module Mm (m~1,   ,S) containing lm SNPs,
there are a total of 3lm combinatory genotypes. Let
Hm~ hm1,   ,hm3lm ðÞ and H’m~ h’m1,   ,h’m3lm ðÞ be the proba-
bilities of occurrences of all combinatory genotypes in the case and
the control populations, respectively. Let nmk and n’mk be the
numbers of occurrences of the k-th combinatory genotype in the
case and the control populations, respectively. The distributions of
Dm and Um, given the parameters Hm and H’m, can be written as
p Dm I,Hm j ðÞ ~ P
3lm
k~1
h
nmk
mk , and p Um I,H’m j ðÞ ~ P
3lm
k~1
h’
n’mk
mk ,
respectively.
Assuming that Hm and H’m follow Dirichlet prior distributions
with hyper-parameters bm~ bm1,   ,bm3lm ðÞ and
b’m~ b’m1,   ,b’m3lm ðÞ , respectively, we integrate out Hm and
H’m and obtain
p Dm I j ðÞ ~
C
P3lm
k~1 bmk
  
C Ndz
P3lm
k~1 bmk
   P
3lm
k~1
C nmkzbmk ðÞ
C bmk ðÞ
, ð3Þ
and
p Um I j ðÞ ~
C
P3lm
k~1 b’mk
  
C Nuz
P3lm
k~1 b’mk
   P
3lm
k~1
C n’mkzb’mk ðÞ
C b’mk ðÞ
: ð4Þ
As the distributions of Dm and Um are independent, we have
p Dm,Um I j ðÞ ~p Dm I j ðÞ p Um I j ðÞ :
Putting the above likelihood functions together, we have the
posterior distribution of I, given the observed genotypes, as
p IjD,U ðÞ !p I ðÞP
S
m~0
p Dm,Um I j ðÞ :
The prior distribution p I ðÞneed to be determined in advance.
For simplicity, we assume that the partition of the loci are
independent, and for each locus, without prior knowledge, the
probability that it belongs to the m-th module is rm (0ƒrmƒ1 and PS
m~0 rm~1). With these two assumptions, we have
p I ðÞ !PS
m~0 rlm
m. Note that when prior knowledge that can be
used to infer the relationship between a locus and the disease risk is
available, the corresponding rm could be updated accordingly. We
assume that all Dirichlet hyper-parameters are equal to 0.5 unless
otherwise specified.
Accounting for LD between Disease Susceptibility SNPs
We use a first-order Markov model to account for the situation
in which a set of SNPs are in LD with a disease susceptibility SNP
in an epistatic module, say, an LD set. For a clear presentation, we
refer to the disease susceptibility SNP as the core SNP and SNPs in
LD with it as peripheral SNPs.
Given a core SNP, the likelihood of the genotypes of a
peripheral SNP in the case population is
P
3
j~1
P
3
k~1
vjk
ojk,
where vjk is the probability that the peripheral SNP has the k-th
genotype conditional on that the core SNP has the j-th genotype,
and ojk is the number of cases for which the core and peripheral
SNPs have the j-th and k-th genotypes, respectively.
Assuming Dirichlet priors with hyper-parameters
cj~ cj1,cj2,cj3
  
for vj~ vj1,vj2,vj3
  
, we integrate out
vj j~1,2,3 ðÞ and obtain the posterior distribution of the genotypes
of the peripheral SNP in the case population conditional on the
core SNP as
P
3
j~1
C
P3
k~1 cjk
  
C
P3
k~1 ojkz
P3
k~1 cjk
   P
3
k~1
C ojkzcjk
  
C cjk
  
0
@
1
A:
Suppose that in a module Mm with lm SNPs, there are cm core
SNPs and lm{cm peripheral SNPs (m~1,   ,S). Let Vc be the set
of peripheral SNPs that are in LD with the c-th core SNP
(c~1,   ,cm). We have that the intersection of any two of these
sets is empty, while the union of all these sets contains all
peripheral SNPs. The posterior distribution of the genotypes of the
set of peripheral SNPs Vc in the case population conditional on the
c-th core SNP is given by
qc~P
i[Vc
P
3
j~1
C
P3
k~1 ccijk
  
C
P3
k~1 ocijkz
P3
k~1 ccijk
   P
3
k~1
C ocijkzccijk
  
C ccijk
  
0
@
1
A,ð5Þ
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the number of cases for which the c-th core SNP has the j-th
genotype, and the i-th peripheral SNP has the k-th genotypes.
Putting Equations (3) and (5) together, the likelihood of the
genotypes in the case population Dm is
p Dm I j ðÞ ~pcore P
cm
c~1
qc,
where pcore is given by Equation (3) as
pcore~
C
P3cm
k~1 bmk
  
C Ndz
P3cm
k~1 bmk
   P
3cm
k~1
C nmkzbmk ðÞ
C bmk ðÞ
:
Similarly, by replacing the case population with the control
population, the likelihood of the genotypes in the control
population Um can be obtained as
p UmjI ðÞ ~ p’core P
cm
c~1
q’c,
where p’core is given by Equation (4) as
p’core~
C
P3cm
k~1 b’mk
  
C Nuz
P3cm
k~1 b’mk
   P
3cm
k~1
C n’mkzb’mk ðÞ
C b’mk ðÞ
,
and q’c is given by
q’c~
P
i[Vc
P
3
j~1
C
P3
k~1 c’cijk
  
C
P3
k~1 o’cijkz
P3
k~1 c’cijk
   P
3
k~1
C o’cijkzc’cijk
  
C c’cijk
  
0
@
1
A,
ð6Þ
where (c’cij1, c’cij2, c’cij3) are Dirichlet hyper-parameters, and o’cijk
is the number of controls for which the c-th core SNP has the j-th
genotype, and the i-th peripheral SNP has the k-th genotypes.
Finally, the likelihood of observing both the case and the control
populations is given by
p Dm,Um I j ðÞ ~p Dm I j ðÞ p Um I j ðÞ : ð7Þ
We also assume that all Dirichlet hyper-parameters are equal to
0.5 unless otherwise specified.
Accounting for LD between Disease Unassociated SNPs
The Bayesian marker partition model described above assumes
independence between SNPs that are unlinked to the disease.
Nevertheless the existence of LD may make distributions of
genotypes of these SNPs dependent. In the model discussed above,
there is no specific module for these linked disease-unassociated
SNPs. As a result, these SNPs could be partitioned into some
epistatic modules and negatively affect the correct partition of
these modules. We therefore propose the use of LD modules to
account for the existence of LD between disease-unassociated
SNPs.
Although the distributions of genotypes for markers in LD are
dependent in both the case and the control populations, as those
for markers in epistatic modules, the underlying principle between
LD markers and epistatic modules are quite different. For LD
markers, the distributions of genotypes are almost the same for the
case and the control populations, while for epistatic modules the
distributions of genotypes are different between the case and the
control populations. In order to incorporate this understanding
into the Bayesian partition model, we assume that other than the S
epistatic modules, there further exist T LD modules, labeled by
{{T,   ,{1}, in each of which loci are in strong LD with each
other.
We also use a first-order Markov model to account for LD
between the SNPs in an LD module. For an LD module Mm
(m~{T,   ,{1), we assume that there exists a core SNP c, and
the distributions of genotypes of all other (peripheral) SNPs in this
LD module depend on the genotype of this core SNP. Let V be
the set of the lm{1 peripheral SNPs that are in LD with the core
SNP. Using similar reasoning as for the epistatic modules, we
obtain that
p Dm,Um I j ðÞ ~p’’coreq’’c:
p’’core is derived with a similar way as Equation (2) and is given by
p’’core~
C
P3
k~1 ak
  
C NdzNuz
P3
k~1 ak
   P
3
k~1
C nmkzn’mkzak ðÞ
C ak ðÞ
,
where nmk and n’mk are the numbers of individuals that have the
k-th genotype at the core SNP in the case and the control
populations, respectively. q’’c is derived with a similar way as
Equation (6) and is given by
q’’c~ P
i[V
P
3
j~1
C
P3
k~1 gcijk
  
C
P3
k~1 ocijkzo’cijk
  
z
P3
k~1 gcijk
  
0
@
P
3
k~1
C ocijkzo’cijkzgcijk
  
C gcijk
  
!
where gcij1,gcij2,gcij3
  
are Dirichlet hyper-parameters, and ocijk
and o’cijk are the numbers of individuals for which the core SNP
has the j-th genotype, and the i-th peripheral SNP has the k-th
genotypes in the case and the control populations, respectively.
We also assume that all hyper-parameters are equal to 0.5 unless
otherwise specified.
With LD modules being incorporated, the posterior distribution
for the generalized indicator vector I~{ T,   ,{1,0,1,   ,S fg
under the generalized Bayesian model is then
p ID ,U j ðÞ !p I ðÞ P
S
m~{T
p Dm,Um I j ðÞ :
Gibbs Sampling Strategy for Marker Partitioning
The posterior distribution of the partition I given by the
above Bayesian partition model suggests the following Gibbs
sampler
pI i~m I {i ½  ,D,U
      
~
pI i~m,I {i ½  ,D,U
  
PS
m’~{T pI i~m’,I {i ½  ,D,U
   , ð8Þ
where m~{T,   {1,0,1,   ,S and I {i ½  ~ I1,   ,Ii{1, ð
Iiz1,   ,ILÞ
0. In order to calculate this sampler in an efficient
way, we compute
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pI i~m,I {i ½  ,D,U
  
pI i~0,I {i ½  ,D,U
  
~
pI i~m,I {i ½ 
  
PS
m’~{T p Dm’,Um’ Ii~m,I {i ½ 
      
pI i~0,I {i ½ 
  
P
S
m’~{T
p Dm’,Um’ Ii~0,I {i ½ 
      
~
pI i~m ðÞ
pI i~0 ðÞ
p D0,U0 Ii~m,I {i ½ 
      
p D0,U0 Ii~0,I {i ½ 
      
p Dm,Um Ii~m,I {i ½ 
      
p Dm,Um Ii~0,I {i ½ 
      
for m~{T,   ,{1,0,1,   ,S, and then obtain
pI i~m I {i ½  ,D,U
      
~
mm PS
m’~{T mm’
:
With this sampler, a Gibbs sampling algorithm can be performed
as follow.
Step 1: Initialization. Assign module labels to indicators Ii for
i~1,   ,L, according to prior probabilities rm
(m~{T,   ,{1,0,1,   ,S).
Step 2: Gibbs sampling. Select an indicator Ii (i~1,   ,L)
at random and update its module label according to the
posterior probabilities pI i~m I {i ½  ,D,U
      
m~{T,   ,{1,0,1,   ,S ðÞ .
Step 3: Repeat the above sampling iteration until conver-
gence or a pre-defined maximum number of iterations
being reached.
In order to calculate the Gibbs sampler, i.e., Equation (8), we
need to partition SNPs in epistatic and LD modules into core
SNPs and peripheral SNPs, say, to obtain structures of the
modules. Besides, the numbers of modules (S and T) are also
unknown. We will address these two questions in the following two
sections.
Obtaining Module Structures
Given a set of SNPs in an epistatic module, we need to partition
the SNPs into non-overlap LD sets. For each LD set, we need to
assign a core SNP. The partition of LD sets, together with the
assignment of a core SNP for each LD set, is referred to as the
structure of an epistatic module.
A naı ¨ve method for obtaining the structure of a module is to
exhaustively search for all possible structures of the module and
then select the one with the maximum likelihood. Specifically, for
an epistatic module Mm (m~1,   ,S) containing lm SNPs, there
are 2lm{1 ways for selecting the core SNPs, corresponding to the
different ways of selecting non-empty subsets from the lm SNPs.
Furthermore, in the case that the number of core SNPs is cm, the
number of ways for associating the rest lm{cm peripheral SNPs to
the core SNPs is cm
lm{cm, since each peripheral SNP can be
assigned to one of the core SNPs, and the assignments are
mutually independent. Obviously, the number of all possible
structures of an epistatic module grows rapidly, making the
exhaustive search strategy practical only when the module
contains a small number of SNPs. We therefore propose the
following sampling approach to search for a reasonable module
structure when the exhaustive search strategy is hard to apply.
For an epistatic module Mm with lm SNPs, in which cm are core
SNPs, and the rest lm{cm are peripheral ones, we index the core
SNPs by numbers from 1 to cm, and we index the peripheral SNPs
by numbers from cmz1 to lm. We further introduce an indicator
vector R~ R1,   ,Rlm ðÞ , representing the status of all SNPs in the
module. In this vector, Ri~0 (i~1,   ,cm) means that the i-th
SNP is a core SNP, and Ri~ki ~cmz1,   ,lm,k~1,   ,cm ðÞ
means that the i-th SNP is a peripheral SNP of the k-th core SNP.
Consider a peripheral SNP indexed by i (cmz1ƒiƒlm). The
posterior distribution of the indicator Ri, given the rest of the
indicators R {i ½  ~ R1,   ,Ri{1,Riz1,   ,Rlm ðÞ and the observa-
tion Dm and Um, can be written as
pR i~k R {i ½  ,Dm,Um
      
~
pR i~k,R {i ½  ,Dm,Um
  
P
0ƒk’ƒcm pR i~k’,R {i ½  ,Dm,Um
  
~
pR i~k,R {i ½ 
  
p Dm,Um Ri~k,R {i ½ 
      
P
0ƒk’ƒcm pR i~k’,R {i ½ 
  
p Dm,Um Ri~k’,R {i ½ 
       ,
where the likelihood function can be calculated in a similar way as
Equation (7). Assuming equal prior probabilities for all possible
structures of the module, the above posterior distribution suggests
the following Gibbs sampler for the peripheral SNP,
pR i~k R {i ½  ,Dm,Um
      
~
p Dm,Um Ri~k,R {i ½ 
      
P
0ƒk’ƒcm p Dm,Um Ri~k’,R {i ½ 
       :ð9Þ
Consider a core SNP indexed by i (1ƒiƒcm). There are two
situations: (1) the core SNP has some peripheral SNPs, and (2) the
core SNP has no peripheral SNPs. In the former case, we need to
fix the indicator Ri~0. In the latter case, a Gibbs sampler can be
obtained as
pR i~k R {i ½  ,Dm,Um
      
~
p Dm,Um Ri~k,R {i ½ 
      
P
0ƒk’ƒcm,k’=i p Dm,Um Ri~k’,R {i ½ 
       ,
ð10Þ
where we exclude the situation in which the core SNP becomes its
own peripheral SNP.
The above Gibbs samplers suggest the following sampling
strategy:
Step 1: Initialization. Generate a random structure.
Step 2: Sampling. Select a SNP at random. If it is a peripheral
SNP, sample its indicator according to Equation (9); if it
is a core SNP with no peripheral SNPs, sample its
indicator according to Equation (10); otherwise keep its
indicator unchanged. After sampling, update the
indices and indicators of the SNPs.
Step 3: Repeat the above sampling step until convergence or
a pre-defined maximum number of iterations being
reached to obtain the posterior distribution of module
structures, and then sample a module structure
according to this distribution.
To further reduce the computational burden, we propose the
following forward and backward strategies that are very economy
in terms of computation time.
In the forward strategy, we consider three situations of adding a
SNP into an existing epistatic module. First, the SNP is itself a core
SNP, and there are no other SNPs in LD with it. Second, the SNP
is in LD with an existing core SNP, and this core SNP remains
unchanged. Third, the SNP is in LD with an existing core SNP,
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with the first case, we try to create a new LD set to include the new
SNP as the core SNP in constant time complexity. To deal with
the second case, we try to add the new SNP as a peripheral SNP to
every existing LD set in linear time complexity, proportional to the
number of existing LD sets. To deal with the third case, we try to
add the new SNP as the core SNP and downgrade the previous
core SNP to a peripheral SNP for every existing LD set in linear
time complexity, also proportional to the number of existing LD
sets. Finally, we compare likelihood values of resulting structures of
the above efforts and select the structure with the highest
likelihood as the new module structure.
In the backward strategy, we also consider three situation of
removing a SNP from an existing epistatic module. First, the
SNP is in LD with a core SNP. Second, the SNP is itself a core
SNP with no other SNPs in LD with it. Third, the SNP is a core
SNP with some other SNPs in LD with it. The first and second
cases can be dealt with in constant time complexity. The third
case can be exhaustively searched for the new core SNP in
linear time complexity, proportional to the number of SNPs in
LD with the removed SNP. By comparing the likelihood values
of these three cases, we can obtain a new structure for the
module.
The exhaustive search strategy can provide optimal module
structures, but its computation time is acceptable only when a
module contains a small number of SNPs. The sampling strategy
takes uncertainty in the partitioning process into consideration
and can alleviate the computational burden when a module
contains a large number of SNPs. The forward and the
backward strategies can greatly reduce the computational
burden and offer sub-optimal module structures. To achieve a
reasonable trade-off between the computational burden and the
optimality of module structures, we also propose a hybrid
strategy in which we mainly perform the forward and the
backward strategies and periodically apply the exhaustive search
or the sampling methods. According to our experience, the
hybrid strategy is much faster than the exhaustive search and
the sampling methods and can yield similar results as the other
two methods in most cases. Therefore, we suggest the use of the
hybrid strategy.
Similar to epistatic modules, we need to also assign a core
SNP for each LD module. However, the situation is quite simple
for obtaining structures for LD modules, because an LD module
has only one core SNP, and thus the number of possible
structures for an LD module is equal to the number of SNPs in
the module. In the exhaustive search strategy, we can search for
the core SNP in linear time complexity, proportional to the
number of SNPs in the module. In the forward strategy, we
consider the situation of adding a SNP into an LD module, and
determine the structure by comparing the likelihood values of
two cases: (1) the added SNP is a peripheral SNP, and (2) the
added SNP is the core SNP. This can be done in constant time
complexity. In the backward strategy, we consider the situation
of removing a SNP from the module. If the removed SNP is not
the core SNP, we simply remove it. In the case that the deleted
SNP is the core SNP, we select a new core SNP from the
previous peripheral SNPs by exhaustive search, which can be
done in linear time complexity, proportional to the number of
SNPs remaining in the module. Since the exhaustive search
strategy is straightforward and already computationally economy
(linear complexity), we simply apply the exhaustive search
strategy to obtain structures for LD modules.
With the module structures being obtained, we are now able to
calculate the Gibbs sampler defined by Equation (8).
Sampling the Number of Modules
We assume that the numbers of epistatic modules (S) and LD
modules (T) are already known in the Gibbs sampling strategy for
marker partitioning. Nevertheless the values of S and T are usually
unknown in real applications. To address the uncertainty of S and
T, we adopt a reversible jump Markov chain Monte Carlo (RJ-
MCMC) procedure [26] as follows.
Step 1: Initialization. Assign S and T with proper positive
numbers (e.g., S=T=1).
Step 2: Gibbs sampling under the current configuration (S,
T). Perform the Gibbs sampling algorithm a number
of n1L iterations using the current S and T. Record
P~p I ðÞ PS
m~{T p Dm,Um I j ðÞ .
Step 3: Propose a new configuration (S0, T0). S and T are
selected at random for updating. Suppose that S is
selected, propose to increase S by 1 (S0/Sz1) with
probability pi or decrease S by 1 (S0/S{1) with
probability pd, where pi§0, pd§0, and pizpd~1.T o
improve the sampling efficiency, we skip the increment
of S (or T) if there are empty modules and the
decrement of S (or T) if it is equal to 1.
Step 4: Gibbs sampling under the proposed configuration (S0,
T0). Perform the Gibbs sampling algorithm a number of
n2L iterations using the proposed S0 and T0. Record
P0~p I ðÞ PS0
m~{T0 p Dm,Um I j ðÞ .
Step 5: Choose a new configuration. Keep the original
configuration (S, T) or accept the new configuration
(S0, T0) according to the acceptance probability, which
is calculated as
a S,T ðÞ / S0,T0 ðÞ ðÞ ~min 1,
P0pd
Ppi
  
if S is increased, or
a S,T ðÞ / S0,T0 ðÞ ðÞ ~min 1,
P0pi
Ppd
  
if S is decreased:
Step 6: Keep repeating steps 2 to 5 all along with the Gibbs
sampling procedure for the posterior distribution of I.
With a sufficient number of the above RJ-MCMC sampling
procedure being repeated, the Markov chains for S and T could
achieve their stable distributions. In our studies, we use
pi~pd~0:5, n1~10, and n2~5.
Statistical Significance of Epistatic Modules
The RJ-MCMC procedure samples the posterior distributions
of the numbers of epistatic and LD modules, while the Gibbs
sampling algorithm gives us the posterior probability that a locus
belongs to a module and enables us to sample the indicators with
the use of their conditional distributions in a sequential way.
Starting from an initial (random) assignment of the indicators, the
Gibbs sampling procedure simulates a Markov chain whose
stationary distribution follows the distribution of the indicator
vector. When the Markov chain reaches its stationary distribution
after a number of burn-in iterations, we record candidate epistatic
modules and their posterior probabilities. The posterior probabil-
ity of an epistatic module represents the strength that the module is
associated with the disease and thus can be directly used to make
statistical inference. For example, biologists can select epistatic
modules with top posterior probabilities for further functional
analysis or biological experiments. Nevertheless, the statistical
significance of epistatic modules might be more desired by
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permutation test method and a ‘‘selection-testing-correction’’
approach for assessing the statistical significance of candidate
epistatic modules.
Permutation test. For a candidate epistatic module, we need
to test H0: the module is not associated with the disease versus H1:
the module is associated with the disease. The posterior probability
of a candidate module represents its strength of association with
the disease and can serve as a test statistic for hypothesis testing.
We therefore propose the following permutation test method on
the basis of posterior probabilities of candidate epistatic modules.
Step 1: Apply the sampling procedure to the original case-
control data with a certain parameter setting. Record
candidate epistatic modules, their module sizes, and
their posterior probabilities. Here, the size of a module
refers to the number of SNPs included in the module.
Step 2: Permute the case-control data by shuffling the case-
control labels. Apply the sampling procedure with the
same parameter setting to the permuted data. Record
the maximum posterior probability of sampled epistatic
modules for each module size.
Step 3: Repeat the above Step 2 a number of N times to obtain
N maximum posterior probabilities for each module
size.
Step 4: For each candidate epistatic module (suppose its size is s)
sampled from the original case-control data, count the
number of times that the N maximum posterior
probabilities for module size s are greater than or equal
to the posterior probability of the candidate module
and divide this count by N to obtain a p-value for the
module.
Selection-testing-correction. Although the permutation test
method can well control the type I error at the expected level, it is
computationally very expensive. To alleviate the computational
burden, we propose the following ‘‘selection-testing-correction’’
approach that uses the standard Chi-squared test with Bonferroni
correction to assess the statistical significance of candidate epistatic
modules.
Step 1: Selection. Apply the Gibbs sampling procedure to the
original data. Collect candidate epistatic modules
whose posterior probabilities are higher than a
predefined threshold.
Step 2: Testing. Apply the Chi-squared test to the selected
modules and obtain their p-values. In this procedure,
the p-value for a module is calculated by applying the
Chi-squared test to check the full interaction of core
SNPs in the module.
Step 3: Correction. Apply the Bonferroni correction to the
above p-values by multiplying them with the number of
all possible tests. For a module with c core SNPs, this
number is
L
c
  
, where L is the total number of SNPs
in the original case-control data.
In the above selection-testing-correction approach, we define
the statistical significance of a module as the Bonferroni corrected
Chi-squared p-value of the full interaction of core SNPs in the
module. There are several reasons to use such a definition. First,
according to our genetic model for complex diseases, it is the core
SNPs that contribute to the disease risk rather than the peripheral
SNPs that are in LD with the core SNPs. It is therefore natural
that we assess the statistical significance of a module on the basis of
the core SNPs. Second, in practice, the introduction of
redundancy of peripheral SNPs in the test procedure will make
the p-values much more conservative, because in the calculation of
the nominal (raw) p-values, the introduction of peripheral SNPs
usually increases the degrees of freedom greatly but does not
increase the values of the Chi-squared statistics much. Therefore
the nominal p-values often tend to be relatively larger. Finally, in
the Bonferroni correction procedure, the inclusion of peripheral
SNPs makes the number of all possible tests even larger, and thus
the correction for multiple testing is more severe. According to our
experiments, the selection-testing-correction approach is compu-
tationally very economy and can achieve similar performance as
the permutation test method.
After epistatic modules being identified by either of the above
methods, one may follow the convention in association studies to
claim some SNPs as representatives of epistatic modules.
Intuitively, core SNPs in the identified module can well serve as
such representatives, as we shall see in the simulation studies.
Nevertheless, we suggest that users of our method also look at
peripheral SNPs besides the attention on core SNPs, because
peripheral SNPs that are in LD with core SNPs also provide useful
information for the understanding of how the disease susceptibility
is being affected, as we shall see in the application of our method
to the real AMD data.
Web Resources
The URL for the software presented herein is as follows: http://
bioinfo.au.tsinghua.edu.cn/epiMODE
Results
Simulation Studies
Disease models. In order to test the power of the proposed
approach in the identification of SNPs that are associated with
disease risks, we design seven disease models with different
characteristics, as illustrated in Table 1. Model 1 contains two
disease loci, each of which contributes to the disease risk
independently. Model 2 is similar to model 1, except that the
disease risk increases only when both loci have at least one disease
allele. Model 3 contains two disease loci, in which the additional
disease allele at each locus does not further increase the disease
risk. Model 4 contains two disease loci and assumes that the
disease allele in one locus has the main effect on the disease risk.
When disease alleles in both loci are present, however, the effect is
inversed. Model 5 has two disease loci in which one locus has
none-zero marginal effect to the disease risk while the other has
absolutely no marginal effect. Model 6 is composed of four disease
loci, partitioned into two epistatic modules, each of which contains
two loci and has the same characteristics as model 4. Model 7 is
composed of four disease loci, partitioned into two epistatic
modules, each of which contains two loci and has the same
characteristics as model 5.
For each of the seven disease models, we simulate eight sub-
models that have different parameter settings. In the first four of
them, we assume that the real causative disease loci are un-
genotyped, and each of them is in linkage disequilibrium (r
2=0.7,
see Text S1 for the calculation of r
2) with a genotyped locus
(marker) that is observable in the data. In the other four, the
disease markers are the real causative disease loci themselves (or
in r
2=1 LD). The minor allele frequencies (MAF) for the disease
markers (the same with the corresponding real causative disease
loci) are 0.05, 0.1, 0.2, and 0.5. Note that the causative disease
loci are independent. For model 1, the marginal effect size (see
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prevalence is set 0.1. For model 2, the marginal effect size for
locus A is set to 0.5, and the disease prevalence is set to 0.01. For
model 3, the marginal effect size for locus A is set to 1.0, and the
disease prevalence is set to 0.1. For model 4 and 6, the parameter
f for the relative risk model that adjusts the effect of disease
genotypes relative to the wild ones is set to 3.0, and the disease
prevalence is set 0.01. For model 5 and 7, the marginal effect size
for locus A (two loci, each of which is in an epistatic module for
model 7) is set to 0.5, and the disease prevalence is set to 0.005.
For each disease model, we simulate 100 data sets for a sub-
model. Each data set contains 1,000 cases and 1,000 controls, in
which 1,000 markers are genotyped for each subject. The random
markers (markers that are not associated with the disease) are also
independent. The minor allele frequency (MAF) for each random
marker is chosen uniformly in [0.05, 0.5]. The detailed
information for generating simulated data for a disease model
with determined parameters is discussed in Text S1.
Comparison with existing methods. In order to illustrate
the performance of the proposed method, we implement
epiMODE, BEAM [23], stepwise logistic regression method [27],
and the classical single-locus Chi-squared test. BEAM uses a
Bayesian model with the Metropolis-Hastings algorithm to
partition disease loci into a group that is composed of loci
‘‘contributing independently to the disease’’ and a group contains
loci ‘‘jointly influence the disease risk’’ [23]. The stepwise logistic
regression method is a two-state strategy. In the first stage, the
most significant 10% SNPs are chosen according to their marginal
effects. In the second stage, all two-way interactions of the chosen
10% SNPs are enumerated and tested for statistical significance,
with marginal effects of the loci being excluded [27]. Besides these
two methods, the classical single-locus Chi-squared test with two
degrees of freedom is used as a benchmark. The details of these
methods are given below.
For the single-locus Chi-squared test, we perform a family of
Chi-squared tests (each for a single SNP) for each simulated data
set. In each test, the null hypothesis is that the SNP under test is
not associated with the disease, and the alternative hypothesis is
that the SNP is associated with the disease. To account for the
multiple testing problem, we apply the Bonferroni correction to
control the family-wise error rate (FWER) at the predefined
significance level (0.05). We claim that a SNP as being identified if
the corrected p-value for the SNP is less than this significance level.
For the stepwise logistic regression method, we perform a family
of logistic regressions with likelihood ratio tests (each for a pair of
SNPs screened out via the single-locus scan) for each simulated
data set. In each likelihood ratio test, the null hypothesis is that the
interaction of the pair of SNPs under investigation is not associated
with the disease, and the alternative hypothesis is that the
interaction of the pair of SNPs is associated with the disease. To
account for the multiple testing problem, we apply the Bonferroni
correction to control the FWER at the predefined significance
level (0.05). We claim both SNPs in a pair as being identified if the
corrected p-value for the pair is less than this level. The details of
this method are given in [27].
For BEAM, a Bayesian approach with a Metropolis-Hastings
algorithm is first applied to each simulated data set to screen out a
small number of candidate SNPs, and then all one-, two-, and
three-way interactions of the candidate SNPs are checked with the
use of a B-statistic [23]. In each test, the null hypothesis is that the
SNP (or interaction of SNPs) under investigation is not associated
with the disease, and the alternative hypothesis is that the SNP (or
interaction of SNPs) is associated with the disease. To account for
the multiple testing correction problem, the Bonferroni correction
is also applied to control the FWER at the predefined significance
level (0.05). We claim all SNPs in an interaction as being identified
if the corrected p-value for the interaction is less than this level.
The details of this method are given in [23].
For epiMODE, the selection-testing-correction scheme is
adopted. For each simulated data set, we set all Dirichlet hyper-
parameters as 0.5 and the prior probability that a SNP belongs to
an epistatic or LD module as 0.01. We run 200L (L is the number
of SNPs in the data set) iterations of the Gibbs sampling
procedure, in which the first half is taken as burn-in, and the
second half is used to record candidate modules and their posterior
probabilities (in every L iterations). In the selection step, all
candidate modules with posterior probabilities higher than a
predefined cut-off (0.20 in our studies) are screened out. In the
testing step, we apply a Chi-squared test to each selected module
and obtain its p-value, as described in the method section. In the
correction step, we again apply the Bonferroni correction to
control the FWER at the predefined significance level (0.05). If the
corrected p-value of a module is less than this level, we report the
module as being identified and further claim core SNPs in the
module as being identified.
For each of the above methods, we count a positive if all disease-
associated SNPs in a simulated data set are identified, and we
calculate the power of the method for a sub-model as the
proportion of positives in all simulated data sets for the sub-model
(100 data sets for each sub-model in our simulation studies).
Therefore, powers are calculated at the same significance level
(0.05) for all methods (verification is provided in Text S1). This
scheme for comparing power is also used in existing literature
[23,27].
The comparison of the powers for the four methods is shown in
Figure 2. For model 1 where the disease loci have no epistatic
interactions, the stepwise logistic regression method has no power
at all, because the marginal effects of the loci is excluded in the
second stage. The other three methods get similar powers, while
epiMODE performs slightly better than the other two (Figure 2A).
Table 1. Relative risk for combinatory genotypes of disease
models.
Disease
Model Locus A Locus B
BB Bb bb
Model 1 AA 1 1+f( 1 +f)
2
Aa 1+f( 1 +f)
2 (1+f)
3
aa (1+f)
2 (1+f)
3 (1+f)
4
Model 2 AA 1 1 1
Aa 1 (1+f)
2 (1+f)
3
aa 1 (1+f)
3 (1+f)
4
Model 3 AA 1 1 1
Aa 1 1+f1 +f
aa 1 1+f1 +f
Model 4 AA 1 1 1
Aa f 1/f 1/f
aa f 1/f 1/f
Model 5 AA 1/(1-MAF)
2 0 1/(1-MAF)
2
Aa 0+f 1/(1- MAF
2-(1-MAF)
2)+f0 +f
aa 0+f0 +f0 +f
doi:10.1371/journal.pgen.1000464.t001
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approximate multiplicative and dominant interactions, respective-
ly. As a result, these loci have non-negligible marginal effects and
can thus be detected by all of the four methods, though the
proposed epiMODE approach generally got moderately higher
power than the others (Figures 2B and 2C). For models with
moderate epistasis (models 4 and 6), epiMODE outperforms
BEAM, and BEAM in turn outperforms the stepwise logistic
regression and the single-locus Chi-squared test (Figures 2D and
2F). For models with strong epistasis in which at least one locus has
Figure 2. Comparison of epiMODE, BEAM, stepwise logistic regression (LR), and the classical single-locus Chi-squared test on seven
disease models (A–G). For each parameter setting, the power is calculated as the proportion of simulated data sets in which all markers associated
with the causative SNPs are indentified at the significance level 0.05 after Bonferroni correction. Each data set contains 1,000 cases and 1,000 controls,
in which 1,000 markers are genotypes for each subject. The absence of bars stands for zero power.
doi:10.1371/journal.pgen.1000464.g002
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outperforms the stepwise logistic regression method. BEAM got a
little power when there is only one epistatic module (model 5) but
lost all the power when there are two modules in the model (model
7). The single-locus Chi-squared test has no power at all no matter
what parameters are selected for the model (Figures 2E and 2G).
Although both the proposed epiMODE approach and the
existing BEAM method rely on the Bayesian inference principle,
the fact that the proposed method achieves significantly higher
power than BEAM results from the following two major reasons.
First, the Gibbs-sampling strategy that updates one locus at a time
conditional on the current status of other markers may be more
suitable for the Bayesian model used here than the Metropolis-
Hastings algorithm that is used by BEAM. Because the dimension
of the indicator vector that represents the property of each marker
is very high, most of the search space has very low probability
density. Consequently, if we randomly choose a vector that has
several factors differing from the current indicator vector, the
probability that the random walk will be rejected is very high,
thereby resulting to an inefficient sampling process. Second, and
may be more fundamental for real human complex diseases rather
than that in our simulation studies where the models used are
relatively simple, the proposed Bayesian partition model takes
multiple epistatic and LD modules into consideration and is
suitable for different disease models, while BEAM could be seen
as, in some sense, a special case of our model in which the number
of epistatic modules is equal to two, and the number of LD
modules is equal to zero. With this understanding, if a case-control
data set is sampled from a disease model that has more than two
epistatic modules with more than one locus in each module, it is
almost impossible for BEAM to identify all modules when the
marginal effects of the loci are subtle.
In contrast to the epiMODE approach, the stepwise logistic
regression method loses its power in both stages. In the first stage,
the stepwise logistic regression does not account for epistatic
interactions, while in the second stage the marginal effect is
excluded from the test statistic. Results for model 1 and model 5
illustrated these disadvantages, respectively. The proposed ap-
proach, however, tends to assign loci with stronger marginal effects
into epistatic modules and then attract loci that have interactions
with the already assigned loci into the same module. Since both
marginal and interactive effects are utilized effectively in the Gibbs
sampling procedure, the proposed approach results in significantly
higher power than the stepwise logistic regression in almost all
simulation models.
Note that we set all Dirichlet hyper-parameters to 0.5 and use
the sampling strategy to obtain module structures. A detailed
analysis shows that epiMODE is robust to the selection of Dirichlet
hyper-parameters (Text S1).
Performance of the permutation test method. In the
above comparison studies, we use the selection-testing-correction
approach to assess statistical significance of epistatic modules.
Although this approach can greatly reduce the computational
burden, it remains interesting to see whether this approach can
achieve comparable performance as the permutation test method.
We therefore compare the powers of the permutation test method
and the selection-testing-correction approach.
The power for the selection-testing-correction approach is
calculated using the method described in the previous section. The
power for the permutation test method is calculated as follows. For
each simulated data set, we run 200L (L is the number of SNPs in
the data set) iterations of the Gibbs sampling procedure, in which
the first half is taken as burn-in, and the second half is used to
record candidate epistatic modules and their posterior probabil-
ities (in every L iterations). After this, we generate 1,000 permuted
data sets for each simulated data set by shuffling the disease labels.
For each permuted data set, we also run the Gibbs sampling
procedure (200L iterations) and record the maximum posterior
probability for each module size. Finally, for each candidate
epistatic module (suppose its size is s), we calculate the proportion
that the recorded maximum probabilities for module size s are
greater than or equal to the posterior probability of the candidate
module to obtain its p-value. If the p-value of a module is less than
a predefined significance level (0.05), we report the module as
being identified and claim core SNPs in the module as being
identified. If all disease-associated SNPs in a simulated data set are
identified, we count a positive. The power of the permutation test
method for a sub-model is then calculated as the proportion of
positives in all simulated data sets for the sub-model (100 data sets
for each sub-model in our simulation studies).
The comparison of the powers of the two methods is shown in
Figure 3. We can see from the figure that the powers of the two
methods are very close to each other for most situations, suggesting
that both approaches work well. We also notice that the
permutation test method can achieve slightly higher power than
the Chi-squared test approach especially for low MAFs and/or
when the disease-associated SNPs themselves are in LD (r
2=0.7 in
the simulation studies) with the un-genotyped causative SNPs.
This observation suggests that the permutation method using
posterior probability may better utilize the LD information to
achieve a high power, as will be analyzed in the next section.
Impact of peripheral SNPs. In the above simulation studies,
we assume independence between genotyped SNPs. In real
genome-wide association studies, however, it is common that a
SNP may be in LD with some other SNPs. We use model 5 as an
example to simulate this situation and to demonstrate the
capability of our approach in dealing with the existence of LD
between SNPs.
In the original model 5, there is an epistatic module in which
two disease susceptibility SNPs contribute to the disease risk
through their interactive effects. In other words, there exist two
core SNPs and no peripheral SNPs in this module. To simulate the
existence of peripheral SNPs, we extend this model by adding two
peripheral SNPs, each in LD (r
2=0.7) with a core SNPs.
Consequently, we have in the extended model an epistatic module
that is composed of two LD sets, each containing a core SNP and a
peripheral SNP. To simulate the existence of LD modules, we
generate four SNPs with MAFs being 0.05, 0.1, 0.2, and 0.5,
respectively. For each of these SNPs, we further add a SNP in LD
(r
2=0.7) with it. Each added peripheral SNP has the same MAF as
the corresponding core SNP. As a result, we have four LD
modules in the extended model, each containing a core SNP and a
peripheral SNP. Since ten more SNPs (two for the epistatic
module and eight for LD modules) are added in the above
modification, we delete ten disease-unassociated SNPs at random
to maintain the total number of SNPs as 1,000.
The performance of epiMODE in the detection of the two
disease susceptibility SNPs for the original and the extended
models under different parameter settings is compared in Figure 4,
in which Figure 4A shows powers of the selection-testing-
correction approach, and Figure 4B shows powers of the
permutation test method. In general, epiMODE achieves higher
power with the addition of SNPs that are in LD with the disease
susceptibility SNPs. Particularly, this observation becomes more
distinct for parameter settings in which the powers of the original
model are quite low (MAFs=0.05 and 0.1). In other words,
epiMODE can be more powerful in detecting disease susceptibility
Epistatic Module Detection with a Bayesian Model
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disease susceptibility ones.
The power of epiMODE with the selection-testing-correction
procedure depends on both the posterior probabilities of epistatic
modules given by the sampling procedure and p-values calculated
by the Chi-squared test with Bonferroni correction. The
improvement in power when peripheral SNPs included is mainly
due to the improvement in the posterior probabilities of the
modules. It is one of the advantages of our Bayesian model that it
can describe the LD between core and peripheral SNPs and then
utilize this information to detect the modules. The inclusion of
peripheral SNPs in a module increases the likelihood of the
observed case-control data and consequently increases the
posterior probability of the module in the sampling procedure,
Figure 3. Comparison of the two methods for obtaining statistical significance for epistatic modules.
doi:10.1371/journal.pgen.1000464.g003
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As a result, the power is improved. Nevertheless, the Chi-squared
statistic, which does not account for LD, may limit the
improvement in power in the testing and correction procedures.
As we can see from Figure 4A, although the powers for most sub-
models are improved when peripheral SNPs are included, the
powers for sub-models in which the disease-associated SNPs are in
LD (r
2=0.7) with the un-genotyped causative SNPs are in general
not higher than the powers for sub-models in which the disease-
associated SNPs are the causative SNPs themselves (r
2=1). This is
natural because the signal of indirect association is usually harder
to be detected [28].
In contrast to the selection-testing-correction approach, the
improvement in power of the permutation test method purely
depends on the increase in the posterior probabilities of epistatic
modules in the sampling procedure and is not restricted by the
post hoc Chi-squared test. Consequently, the permutation test
method achieves higher power when peripheral SNPs are included
in most cases, especially when the disease-associated SNPs (core
SNPs) are in LD (r
2=0.7) with the un-genotyped causative SNPs
(Figure 4B). We also notice that, the power (0.98) for the second
sub-model (MAF=0.1, r
2=0.7) that includes peripheral SNPs is
much higher than the power (0.76) for the sixth sub-model
(MAF=0.1, r
2=1) that contains no SNPs in LD with the disease-
associated SNPs. This observation suggests that, with the
integration of LD information, epiMODE is capable of detecting
indirect subtle associations in which the causative SNPs are un-
genotyped. With the development of genotyping (and sequencing)
technology, genome-wide case-control data become more and
more dense, and more LD information will be supplied.
epiMODE, with its capability of utilizing LD information, is
especially suitable for this kind of data.
Distribution of the number of modules. We use model 7
as an example to demonstrate the performance of the RJ-MCMC
procedure in addressing the uncertainty of the numbers of epistatic
and LD modules. In the original model 7, there exist two epistatic
modules, each containing two disease susceptibility SNPs. We
extend the seventh parameter setting for model 7, in which the
MAFs for all disease loci are 0.2, and the disease markers are the
real disease causative loci themselves (r
2=1). To simulate the
existence of LD modules, we generate four SNPs with MAFs being
0.05, 0.1, 0.2, and 0.5, respectively. For each of these SNPs, we
further add a SNP in LD (r
2=0.7) with it. Each added peripheral
SNP has the same MAF as the corresponding core SNP.
Consequently, we have four LD modules in the extended model,
each containing a core SNP and a peripheral SNP. Since eight
SNPs are added in the above procedure, we delete the same
number of disease-unassociated SNPs at random to maintain the
total number of SNPs as 1,000.
For the extended model in which S=2 and T=4, we apply
epiMODE to detect the disease susceptibility SNPs, and we record
the traces of the numbers of epistatic and LD modules sampled by
the RJ-MCMC strategy. The results are shown in Figure 5.
Starting from initial values (S=T=1), the Markov chain gradually
reaches its stationary distribution. Specifically, after the burn-in
(100L iteration), the probabilities for S to be 1, 2 and 3 are 0.0389,
0.5767 and 0.3844, respectively, and the probabilities for T to be
3, 4 and 5 are 0.0778, 0.5889 and 0.3333, respectively. These
results suggest that the RJ-MCMC strategy is effective in handling
the uncertainty of the numbers of epistatic and LD modules.
A Genome-Wide Association Study on AMD
In order to verify the capability of the proposed approach in the
detection of epistatic interactions in real genome-wide association
studies, we apply epiMODE to an Age-related Macular Degener-
ation (AMD) data set [20], which contains 103,611 SNPs
genotyped with 96 cases and 50 controls.
The authors of the original paper reported that two SNPs,
rs380390 and rs1329428, were believed to be significantly
associated with AMD. Our method successfully indentifies both
of the two SNPs through the identification of an epistatic module
that included these two SNPs (two more SNPs are also indentified
in the same epistatic module, and the posterior probability of the
module is above 0.9, see Figures 6 and 7). The nominal p-values
for rs380390 and rs1329428 are 1.75610
26 and 3.64610
26,
respectively, according to the Chi-squared test with two degrees of
freedom. Our method also indentifies two novel SNPs, rs1394608
and rs3743175, by detecting an epistatic module that includes
both loci (two more SNPs in LD with them are also indentified in
the same epistatic module, and the posterior probability of the
module is greater than 0.9, see Figures 6 and 7). The nominal p-
values for these two SNPs are 8.81610
25 and 1.76610
23,
respectively, according to the Chi-squared test with two degrees
of freedom. Note that the p-value for the combination of
Figure 4. Performance of epiMODE on disease models with and without peripheral SNPs. (A) Results of the selection-testing-correction
approach. (B) Results of the permutation test method. The original model 5 is used as the disease model without peripheral SNPs. The extended
model 5 in which each of the two core SNPs has a peripheral SNPs is used as the disease model with peripheral SNPs.
doi:10.1371/journal.pgen.1000464.g004
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27, while the p-value for the
combination of rs380390 and rs1329428 is only 1.84610
25,
according to the Chi-squared test with eight degrees of freedom.
The distributions of the combination of rs1394608 and
rs3743175 in cases and controls are shown in Figures 8A and
8B, respectively. According to Chi-squared tests with four degrees
of freedom, these two SNPs are independent in controls (p-
value=7.50610
21) and dependent in cases (p-value=3.27610
23).
We also infer the genotype frequencies of the combination of these
two SNPs according to their distributions in controls and the
Hardy-Weinberg equilibrium (HWE), and we further infer the
penetrance for the combination of these two SNPs according to
their distributions in cases and the inferred genotype frequencies,
as shown in Figure 8C (see Text S1 for details of inferring
genotype frequencies and the penetrance). The penetrance of
genotypes of rs1394608 differs stronger from that of rs3743175,
suggesting that rs1394608 may be the dominant locus for disease
susceptibility. Specifically, the homozygote TT of rs1394608 is
responsible for disease risk significantly higher than the heterozy-
gous and the other homozygous genotype. However, the effect of
rs1394608 is strongly regulated by rs3743175, especially for the
homozygous genotype TT of rs1394608. The penetrance for the
combination genotype TT/CC (for rs1394608 and rs3743175,
respectively), is 9.64610
22, significantly larger than the pene-
trance for the combination genotype TT/CT and the penetrance
for the combination genotype TT/TT. Odds ratio values in table 2
also give similar results. From the above analysis, we infer that the
relationship between the combination of SNPs rs1394608 and
rs3743175 and the disease risk is a classic epistatic interaction, in
which one dominant variant locus (rs1394608) is regulated by the
other locus (rs3743175). In the following part, we perform
functional analysis of these two SNPs.
AMD is the primary cause of irreversible visual loss in the
Western world [29]. The clinical hallmark of AMD is pathological
extracellular deposits in retinal called drusen. Previous single-locus
studies have identified the complement factor H (CFH) and the
HtrA serine peptidase 1 (HTRA1) as two major risk genes for
AMD [30–32]. Despite the complex etiology of AMD, no
significant epistasis has been identified by BEAM in the genome-
wide case-control data used in this study.
The most significant epistatic effect we identified is between
SNPs rs1394608 and rs3743175. Interestingly, there is another
SNP rs2828155 with exactly the same genotype distribution as
rs3743175 among all case/control samples (rs2828155 is also
detected by epiMODE in the same module with rs1394608 and
rs3743175, see Figures 6 and 7); therefore the epistasis may also
exist between rs1394608 and rs2828155.
rs1394608 resides within the intron of SGCD, a gene located on
chromosome 5q33-34, which has been implicated in AMD [33,34]
and predispose to drusen formation [35]. SGCD is the delta subunit
of the sarcoglycan complex, a component of the dystrophin-
glycoprotein complex, linking the cytoskeleton to the extracellular
matrix. The sarcoglycan complex involves in plasma membrane
deposition, and the co-expression of SGCD and SGCB (beta
subunit) is responsible for delivery to and retention of sarcoglycan
complex at the cell surface [36]. Defects in SGCD are the cause of
limb-girdle muscular dystrophy type 2F (LGMD2F) and dilated
cardiomyopathy 1L (CMD1L). The detected SNP rs1394608,
together with all 16 SNPs of strong LD (r
2.0.8) within 1 Mb
neighboring region, are all significantly associated with the
expression of FBLN1 (p-value,1610
27, according to [37]), a
gene belongs to the fibulin family of extracellular matrix proteins.
Other members (FBLN3, FBLN5, FBLN6) of the family have been
associated with AMD [38–41], and various evidences support that
FBLN1 may also play a role in AMD [39,42–45]. Specifically,
FBLN1 can act as a cofactor for the matrix metalloprotease
ADAMTS1 and play important roles in the degradation of
proteoglycans by ADAMTS1 during pathological conditions
induced by inflammatory processes [46]. Therefore variants in
SGCD may lead to AMD in a similar way to HTRA1, which may
regulate the degradation of extracellular matrix by facilitating
access of other degradative matrix enzymes, such as matrix
metalloproteinases to their substrates [47].
Figure 5. Distributions of the numbers of epistatic and LD
modules. Model 7 with parameters MAF=0.2 and r
2=1 is extended to
include two epistatic modules and four LD modules. Results are
obtained with parameters n1=10 and n2=5.
doi:10.1371/journal.pgen.1000464.g005
Figure 6. Posterior probabilities of epistatic modules identified
in the AMD data set. The prior probability that a marker is involved in
a module is set to 10/103611. The cutoff posterior probability for
reporting an epistatic module is 0.9.
doi:10.1371/journal.pgen.1000464.g006
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gene located on chromosome 15q24. Iyengar et al [34] have also
identified linkage signal for a marker in the nearby locus 15q21.
A weak linkage signal on chromosome 15q has also been
observed in another full-genome scan [48]. Further, translocation
of 15q24 had been found in a patient with visible disc drusen
[49]. Sequence analysis [50] identified in SCAPER an unstable
non-coding tandem repeat, an important form of mutation
responsible for several neurological, neurodegenerative and
neumuscular disorders [51]. The detected SNP rs3743175 has
Figure 7. Structures of epistatic modules identified in the AMD data set. Double arrowheads connect core SNPs in epistatic modules. Single
arrowheads link peripheral SNPs to core SNPs.
doi:10.1371/journal.pgen.1000464.g007
Figure 8. Distributions of genotypes of rs1394608 and rs3743175 in the AMD data set and the penetrance estimated for
combinatory genotypes of these two SNPs. (A) The distribution of genotypes of rs1394608 and rs3743175 in the case population. (B) The
distribution of genotypes of rs1394608 and rs3743175 in the control population. (C) The estimated penetrance for the combination of rs1394608 and
rs3743175, assuming that the disease prevalence is 0.01. The relative values for the penetrance maintain the same when the population prevalence is
alternatively assumed. It is shown that rs1394608 could be seen as the dominant-effect locus for the disease risk, and its effect is strongly regulated
by rs3743175.
doi:10.1371/journal.pgen.1000464.g008
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value=9.5610
214).
The mechanism for the epistasis between rs1394608 in SGCD
and rs3743175 in SCAPER is unclear. We speculate that SCAPER
may exert influence to SGCD susceptibility through the regulation
of aging process, as evidences show both genes are involved in cell
cycle regulation and DNA repair. eQTL analysis [37] shows that
rs1394608 is significantly associated with the expression of RAD9B
(p-value,1610
27), a novel component of the 9-1-1 cell-cycle
checkpoint response complex [52], while rs3743175 is significantly
associated with the expression of SCAPER, a novel regulator of cell
cycle progression [53]. We also find that the DNA repair gene
ERCC6, which plays roles in the aging process and predisposes to
AMD [54], is significantly (p-value,1610
24) co-expressed with
SGCD and SCAPER across more than 40 human tissues [55]. Co-
expression analysis also finds that both SGCD and SCAPER are
significantly correlated with MASP1 (p-value,1610
22) and
MASP2 (p-value,1610
25), activators of the complement pathway.
Together with the report of synergic effect between ERCC6 and
CFH in predisposing AMD [54], the above analyses suggest clues
for the link between the aging component and the immune
component in the etiology of AMD.
The third SNP rs2828155 locates in an about 4 Mb intergenic
region in chromosome 21q21.1, a region has also been implicated
in AMD [35]. ADAMTS1 and ADAMTS5 lie about 4 Mb
downstream of the SNP. There is possibility that rs2828155 may
regulate the expression of these two enzymes, and then the
epistasis between rs2828155 and rs1394608 is more straightfor-
ward: rs2828155 regulates the enzyme ADAMTS1 and rs1394608
regulates FBLN1.A sFBLN1 can act as a cofactor of ADAMTS1
and plays an important role in the degradation of proteoglycans by
ADAMTS1 during pathological conditions induced by inflamma-
tory processes [46], it is possible that rs2828155 and rs1394608
have epistatic effect in AMD. Linkage signals for AMD from the
two loci have been detected in the same linkage scan [35].
In summary, our association study suggests the existence of
epistasis in AMD, while the functional analysis provides new
insights for the understanding of the epistasis from the biological
point of view. Certainly, further work, especially experimental
verification of the above epistasis, is necessary in order to confirm
the roles of the identified SNPs and their epistasis in AMD.
A Genome-Wide Association Study on Parkinson’s
Disease
We further apply our approach to a genome-wide case-control
data set of Parkinson’s disease [21,22], which contains 408,803
SNPs genotyped with 270 cases and 271 controls. With the use of
epiMODE, we identify 12 independent contributing markers with
posterior probabilities of associations greater than or equal to 0.9.
The p-values for these markers, obtained by Chi-squared tests with
two degrees of freedom, are shown in Table 3, which suggest that
7 out of the 12 markers are statistically significantly. The original
paper [21] only tests SNPs that give successful genotypes in more
than 95% samples. As a result, the significant markers identified by
our method are all excluded. In our analysis, we run our method
on the original data without discarding any SNP.
The fact that no interaction effect is detected may be partly due
to the disease model itself, which may have no strong interaction
effects. Another reason may be the missing genotype problem that
aggravates the insufficiency of the sample size in mapping epistatic
effects. In the detection of a k-locus interaction, if the genotype
missing rate is ri (i~1,   ,k) for each locus, the expected
percentage of samples that could be used is only Pk
i~1 1{ri ðÞ ,
which decreases fast with k, the number of loci in the interaction,
and makes the power for detecting high-order interactions even
lower.
Discussion
In this paper, we explicitly define epistatic modules as basic
genetic units that influence the disease susceptibility and put
forward a Bayesian marker partition model to explain the
observed case-control data. We develop a Gibbs sampling strategy
to simulate the posterior distributions that markers belong to
epistatic modules and further resort to hypothesis testing to screen
out statistically significant modules. We extensively assess the
effectiveness of the proposed epiMODE approach. In simulation
studies, epiMODE significantly outperforms all other methods. In
the application to the Age-related Macular Degeneration (AMD)
data, epiMODE successfully identifies two loci that are known to
be associated with the disease, and suggests the epistatic
interaction of two other loci. In the application to the Parkinson’s
disease data, epiMODE identifies seven loci that might contribute
to the disease susceptibility.
The success of the proposed approach can be attributed to a
combination of several aspects. First, with the explicit definition of
Table 2. Odds ratios for rs3743175 in SCAPER and rs1394608
in SGCD.
SNP SGCD rs1394608
TT TC CC
SCAPER
rs3743175
TT 10.67 (0.98, 115.68)1.65 (0.16, 17.47)1.00
TC 30.67 (2.52, 373.55)9.60 (0.95, 96.92)10.67 (0.82, 138.22)
CC 60.00 (3.04,
1185.03)
0.00 Inf
Odds ratios with 95% confidence intervals in parentheses were calculated to
compare each genotypic combination to the baseline of homozygosity for
common allele at rs3743175 and less common allele at rs1394608 (TT/CC).
doi:10.1371/journal.pgen.1000464.t002
Table 3. p-values for SNPs with posterior probabilities greater
than or equal to 0.9.
Index in the data dbSNP ID p-value
6321 rs12069733 1.77610
27
52635 rs6757197 6.89610
27
122959 rs1504212 4.31610
28
142148 rs557074 4.60610
28
172163 rs850084 2.20610
28
177104 rs6460033 4.45610
27
201738 rs7846412 5.13610
27
215060 rs10963676 5.46610
28
234666 rs2666781 5.16610
27
240134 rs4746675 8.03610
28
257981 rs12364577 9.21610
28
358054 rs9952724 7.78610
210
The nominal p-value for Bonferroni corrected significant level of 0.05 is
1.22610
27.
doi:10.1371/journal.pgen.1000464.t003
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epistatic interactive effects of multiple loci in a native way. Second,
the incorporation of LD information between markers in epistatic
modules greatly improves the power of our method in the
detection of indirect subtle associations. Third, the introduction of
LD modules further minimizes the possibility of assigning disease-
unassociated loci into epistatic modules. Fourth, the Gibbs
sampling strategy is effective in obtaining the posterior distribu-
tions that disease-associated loci belong to epistatic modules.
Finally, the native identification of interactive effects of multiple
loci (epistatic modules) instead of enumerating combinations of
SNPs makes our approach capable of and suitable for dealing with
large scale case-control data.
Our marker partition model is proposed from the Bayesian
perspective, and thus a natural advantage of this model is its
capability of incorporating prior biological knowledge about
individual SNP markers, such as their locations (e.g., coding
region, promoter region, etc.), genotype frequencies, and LD
information. Nevertheless, some parts in our approach are not
formulated from the pure Bayesian perspective, mainly for the
consideration of reducing the computational burden. Structures of
epistatic modules are represented by results of searching
procedures (exhaustive/sampling/greedy) rather than averaged
over all possible structures according to their posterior probabil-
ities because this part is heavily used by the up-level Gibbs
sampling algorithm. The standard Chi-squared test with Bonfer-
roni correction is also much more computationally economy than
the permutation test method. Such efforts for greatly reducing the
computational burden are necessary in handling large scale case-
control data sets, which may contain more than 500,000 SNPs and
have been very common in recent genome-wide association
studies.
Certainly, the proposed approach can further be improved from
the following directions. First, the assumption of equal values for
all Dirichlet priors in the Bayesian marker partition model is
obviously for the purpose of seeking for simplicity. Although
different priors do not yield very different results, careful selection
of priors is still worth investigating. One possibility is to
systematically minimize the impact of priors using techniques
such as prior annealing [56]. Another possibility is to select priors
that reflect existing biological knowledge, such as the rich
genotype frequency and LD information from the International
HapMap Project [57,58]. Second, although our experience
suggests that the current Gibbs sampling strategy works well,
some sophisticated sampling strategy such as the ‘‘split-merge’’
algorithm [59] might be incorporated to further improve the
efficiency of the sampling strategy. Finally, currently we do not
formulate the marker partitioning procedure from the viewpoint of
mixture models, such as the Dirichlet process (DP) mixture model.
Since a DP mixture model assumes an infinite number of mixture
components and thus provides more flexibility in controlling the
complexity of the model [60,61], it would be interesting to explore
the possibility of incorporating the DP mixture model into
genome-wide association studies.
Supporting Information
Text S1 Epistatic module detection for case-control studies: a
Bayesian model with a Gibbs sampling strategy.
Found at: doi:10.1371/journal.pgen.1000464.s001 (0.21 MB PDF)
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